The current stock price of LSB is 0.627 USD. In the past month the price decreased by -25%. In the past year, price decreased by -18.57%.
ChartMill assigns a fundamental rating of 2 / 10 to LSB. LSB may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months LSB reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 87.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.31% | ||
| ROE | -20.01% | ||
| Debt/Equity | 0.05 |
5 analysts have analysed LSB and the average price target is 31.62 USD. This implies a price increase of 4943.06% is expected in the next year compared to the current price of 0.627.
For the next year, analysts expect an EPS growth of 105.67% and a revenue growth 75.61% for LSB
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 394.886B | ||
| AMGN | AMGEN INC | 17.06 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.1 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.99 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 13.22 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.54 | 21.279B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 573 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
LAKESHORE BIOPHARMA CO LTD
Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District
Beijing BEIJING CN
Employees: 573
Phone: 17327133678
LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 573 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
The current stock price of LSB is 0.627 USD. The price decreased by -20.68% in the last trading session.
LSB does not pay a dividend.
LSB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
LAKESHORE BIOPHARMA CO LTD (LSB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).
The Revenue of LAKESHORE BIOPHARMA CO LTD (LSB) is expected to grow by 75.61% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
You can find the ownership structure of LAKESHORE BIOPHARMA CO LTD (LSB) on the Ownership tab.